{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:35:00Z","timestamp":1788471300512,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115190","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T04:12:39Z","timestamp":1675915959000},"page":"115190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors"],"prefix":"10.1016","volume":"250","author":[{"given":"Ningjie","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-3721","authenticated-orcid":false,"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115190_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm3683","article-title":"Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death","volume":"14","author":"Ofengeim","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115190_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107979","article-title":"Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment","volume":"231","author":"Li","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115190_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer's disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.ejmech.2023.115190_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115190_bib5","doi-asserted-by":"crossref","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","article-title":"RIPK1 mediates a disease-associated microglial response in Alzheimer's disease","volume":"114","author":"Ofengeim","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115190_bib6","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1038\/cddis.2012.176","article-title":"Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models","volume":"3","author":"Takahashi","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115190_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41419-019-1735-6","article-title":"Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis","volume":"10","author":"Hou","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115190_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13608","article-title":"RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis","volume":"513","author":"Dannappel","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115190_bib9","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.1901179116","article-title":"Targeting RIPK1 for the treatment of human diseases","volume":"116","author":"Degterev","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115190_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tips.2020.01.002","article-title":"Inhibitors targeting RIPK1\/RIPK3: old and new drugs","volume":"41","author":"Martens","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115190_bib11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cell.2009.05.021","article-title":"Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115190_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nchembio.83","article-title":"Identification of RIP1 kinase as a specific cellular target of necrostatins","volume":"4","author":"Degterev","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115190_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115190_bib14","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/cdd.2012.90","article-title":"TRAIL induces necroptosis involving RIPK1\/RIPK3-dependent PARP-1 activation","volume":"19","author":"Jouan-Lanhouet","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2023.115190_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.immuni.2016.06.007","article-title":"RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4","volume":"45","author":"Najjar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115190_bib16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115190_bib17","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1021\/jm061016o","article-title":"StructureActivity relationship study of tricyclic necroptosis inhibitors","volume":"50","author":"Jagtap","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","article-title":"Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115190_bib19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","article-title":"DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors","volume":"59","author":"Harris","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio711","article-title":"Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury","volume":"1","author":"Degterev","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115190_bib21","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1016\/j.bmcl.2005.07.077","article-title":"Structure-activity relationship study of novel necroptosis inhibitors","volume":"15","author":"Teng","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115190_bib22","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/acs.jmedchem.9b01317","article-title":"Small-molecule inhibitors of necroptosis: current status and perspectives","volume":"63","author":"Zhuang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib23","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.jmedchem.7b01647","article-title":"Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure-kinetic relationships","volume":"61","author":"Yoshikawa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","article-title":"Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases","volume":"60","author":"Harris","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.365","article-title":"Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers","volume":"5","author":"Weisel","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2023.115190_bib26","series-title":"Potent and Selective RIPK1 Inhibitors Targeting Dual\u2010Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis","author":"Yang","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115190_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113484","article-title":"Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors","volume":"220","author":"Xia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114345","article-title":"Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors","volume":"236","author":"Hao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acsmedchemlett.9b00108","article-title":"Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer","volume":"10","author":"Harris","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115190_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acs.jmedchem.6b01196","article-title":"Discovery of a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome","volume":"60","author":"Ren","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib31","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.1021\/acs.jmedchem.2c01478","article-title":"Discovery of a trifluoromethoxy cyclopentanone benzothiazole receptor-interacting protein kinase 1 inhibitor as the treatment for Alzheimer's disease","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115190_bib32","article-title":"Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115190_bib33","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/febs.14176","article-title":"Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis","volume":"284","author":"Le Cann","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115190_bib34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.immuni.2011.09.020","article-title":"RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome","volume":"35","author":"Duprez","year":"2011","journal-title":"Immunity"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:42Z","timestamp":1759330242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"alternative-id":["S0223523423001058"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115190","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115190"}}